Companies Dominating the Tenosynovial Giant Cell Tumor Landscape
- Abbisko Therapeutics
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Ammax Bio Inc.
- HUTCHMED
- SynOx Therapeutics Limited
- Deciphera Pharmaceuticals Inc.
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Amgen Inc.
- Celleron Therapeutics Limited
- Takeda Pharmaceutical Company Limited.
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of tenosynovial giant cell tumor is evaluated at USD 8.7 billion.
The tenosynovial giant cell tumor market size was valued at USD 8.42 billion in 2024 and is set to exceed USD 13.85 billion by 2037, registering over 3.9% CAGR during the forecast period i.e., between 2025-2037. Increasing cases of tenosynovial giant cell tumor diseases in almost all age groups people will fuel the market growth.
North America industry is likely to dominate majority revenue share of 43% by 2037, driven by manufacturing and approvals of new novel drugs for tenosynovial giant cell tumors in the region.
The major players in the market are Abbisko Therapeutics, Ammax Bio Inc., HUTCHMED, SynOx Therapeutics Limited, Deciphera Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Amgen Inc., Celleron Therapeutics Limited, Takeda Pharmaceutical Company Limited., Daiichi Sankyo Company, Limited., Chugai Pharmaceutical Co., Ltd., CHEPLAPHARM Arzneimittel GmbH, Ono Pharmaceutical Co., Ltd.
